Skip to main content
SpringerLink
Log in

Evaluation of trifluperidol in chronic schizophrenia

  • Original Investigations
  • Published:
Psychopharmacologia Aims and scope Submit manuscript

Summary

Trifluperidol, a new butyrophenone compound, was evaluated in chronic schizophrenic women under conditions of a controlled clinical trial. Within this framework significant drug effects associated with the standard drug, chlorpromazine, attested to the sensitivity of the experiment, while trifluperidol, the experimental drug, was shown to be an antipsychotic agent at least equally as effective as the standard.

The placebo group tended to deteriorate on all measures. This trend did not differ significantly from a similar trend in a group of subjects receiving neither placebo nor active treatment. The most likely explanation for this deterioration is thought to be an inadequate preliminary dry-out period, although other influences affecting all subjects adversely can not be ruled out.

The demonstration of significant drug:placebo differences was dependent in part upon the presence of the negative change in the placebo group. Failure to include a control group in the present study would have precluded the demonstration of statistically significant drug effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Clark, M. L., T. S. Ray, A. Paredes, J. P. Costiloe, J. S. Chappell, J. A. Hagans, and S. Wolf: Chlorpromazine in chronic schizophrenic women: I. Experimental design and effects at maximum point of treatment. Psychopharmacologia (Berl.) 2, 107–136 (1961).

    Google Scholar 

  • Fink, M., A. Don, T. Itil, M. A. Stallings, and J. M. C. Holden: Trifluperidol in the treatment of psychosis: Observations suggestive of antioholinergic activity at higher dosages. J. New Drugs 6, (3), 174–181 (1966).

    Google Scholar 

  • Fox, W., I. F. Gobble, M. Clos, and E. Denison: A clinical comparison of trifluperidol, haloperidol and chlorpromazine. Curr. ther. Res. 6, 409–415 (1964).

    Google Scholar 

  • Gallant, D. M., M. P. Bishop, E. Timmons, and C. A. Steele: Trifluperidol: A butyrophenone derivative. Amer. J. Psychiat. 120, 485–487 (1963).

    PubMed  Google Scholar 

  • Hollister, L. E., J. E. Overall, J. L. Bennett, I. Kimbell jr., and J. Shelton: Triperidol in newly admitted schizophrenics. Amer. J. Psychiat. 122, 96–98 (1965).

    Google Scholar 

  • Modell, W., and R. W. Houde: Factors influencing clinical evaluation of drugs with special reference to the double-blind technique. J. Amer. med. Ass. 167, 2190–2198 (1958).

    Google Scholar 

  • Pratt, J. P., M. P. Bishop, and D. M. Gallant: Comparison of haloperidol, trifluperidol, and chlorpromazine in acute schizophrenic patients. Curr. ther. Res. 6, 562–571 (1964a).

    Google Scholar 

  • — — —: Trifluperidol and haloperidol in the treatment of acute schizophrenia. Amer. J. Psychiat. 121, 592–594 (1964b).

    PubMed  Google Scholar 

  • Tiffin, J., and E. J. Asher: The purdue peg board: Norms and studies of reliability and validity. J. appl. Psychol. 32, 234–247 (1948).

    Google Scholar 

  • Wechsler, D.: Manual for the Wechsler adult intelligence scale (WAIS). New York: Psychological Corp. 1955.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Central State Griffin Memorial Hospital, Norman, Oklahoma, USA

    Mervin L. Clark M. D.

Authors
  1. Mervin L. Clark M. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang K. Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adrian A. Kyriakopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas S. Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John P. Colmore
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Rudy Ramsey
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Triperidol®, McNeil Laboratories, Inc., Fort Washington, Pennsylvania.

From the Department of Medicine, and the Experimental Therapeutics Unit. University of Oklahoma Medical Center and Central State Griffin Memorial Hospital, Norman, Oklahoma.

Presented in part to the American College of Clinical Pharmacology and Chemotherapy, Chicago, Illinois, November 4, 1965, an abstract of which appeared in Journal of New Drugs, July–August, 1965.

This study was supported in part by grants MH-04260 and MH-11666 from the National Institute of Mental Health, United States Public Health Service, Bethesda, Maryland, and a grant in aid from the McNeil Laboratories, Inc., Fort Washington, Pennsylvania. Statistical analyses were carried out in collaboration with the Biostatistical Unit and Computer Facility, Department of Preventive Medicine and Public Health, University of Oklahoma Medical Center, Oklahoma City, Oklahoma.

The authors are indebted to Kit C. Farwell, Ph. D., and Lee Little, Ph. D., for a part of the psychological testing; to William H. Dickinson, B. A., for a part of the psychological testing and help with the statistical analysis; to Mrs. Agnes Barkett, R. N., and the Ward Staff for behavior ratings and patient care.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clark, M.L., Huber, W.K., Kyriakopoulos, A.A. et al. Evaluation of trifluperidol in chronic schizophrenia. Psychopharmacologia 12, 193–203 (1968). https://doi.org/10.1007/BF00403773

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00403773

Keywords

Search

Navigation